Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb Renews Call For New Opioid Review Paradigm As Democrats Prepare For House Control

Executive Summary

US FDA's controversial approval of Dsuvia may prompt incoming House Democrats to pay special attention to commissioner's remarks on how agency reviews opioids. 
Advertisement

Related Content

Opioid Prescribing Guidelines Will Be More Template Than Commandment
Mallinckrodt's Abuse-Deterrent Oxycodone IR May Face Hurdle At US FDA Panel
US FDA May Largely Avoid House Democrats' Investigation Agenda
Dsuvia Approval May Be Followed By New Opioid Review Paradigm At FDA
Opioid Policy At US FDA: Over-Promising Or Overreacting?
Public Citizen: US FDA Deliberately Excluded Risk Committee From Dsuvia Panel To Get Positive Vote
Dsuvia's Thumbs Up From US FDA Advisory Panel Is First Positive Vote For An Opioid In 2018
Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes
AcelRx's Sublingual Opioid Dsuvia Brings Unique Risk To Advisory Panel: Dropped Tablets
Opioid REMS Increases Nearly Six-Fold As US FDA Adds Immediate-Release Products

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124224

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel